February 2021.
Improving our response to the ongoing COVID-19 pandemic in Africa requires regularly updated information, constant innovation, and considerable support towards research and development (R&D) for priorities that respond to the African realities. Shaping the research agenda and stimula...ting the generation, translation, and dissemination of valuable knowledge is one of the core functions of the African Academy of Sciences (AAS), African Centre for Disease Control (Africa CDC), and WHO-AFRO. We need answers to a list of critical research questions that respond to the current realities on the African continent to guide the COVID-19 outbreak control efforts
more
In this unit we will learn about COVID-19 and Testing - the role of the laboratory in the pandemic.
Jesuit Worldwide Learning invites you to learn facts and test your knowledge on the ongoing pandemic caused by Coronavirus (COVID 19) through a fun-interactive crash course! Access is free! You have ...only to sign up
more
The case for evidence- based communication of science
On this site WHO is gathering the latest scientific findings and knowledge on coronavirus disease (COVID-19) and compiling it in a database. They are updating the database daily from searches of bibliographic databases, hand searches of the table of contents of relevant journals, and the addition of... other relevant scientific articles that come to our attention. The entries in the database may not be exhaustive and new research will be added regularly.
more
Find a weekly, country specific update at: http://polioeradication.org/polio-today/polio-now/this-week/
PLoS Negl Trop Dis 10(3): e0004530 -Published: March 2, 2016
This paper reviews the status of the Zika virus outbreak, including medical countermeasureoptions, with a focus on how the epidemiology, insect vectors, neuropathology, virology and immunology inform options and strategies available for m...edical countermeasure development and deployment.
Please download directly from the website Open Access: http://journals.plos.org/plosntds/article/asset?id=10.1371%2Fjournal.pntd.0004530.PDF
more
Environmental Research Volume 151, November 2016, Pages 115-123
Dengue is the world’s most important arboviral disease in terms of number of people affected. Over the past 50 years, incidence increased 30-fold: there were approximately 390 million infections in 2010. Globalization, trade, travel,... demographic trends, and warming temperatures are associated with the recent spread of the primary vectors Aedes aegypti and Aedes albopictus and of dengue. Overall, models project that new geographic areas along the fringe of current geographic ranges for Aedes will become environmentally suitable for the mosquito’s lifecycle, and for dengue transmission. Many endemic countries where dengue is likely to spread further have underdeveloped health systems, increasing the substantial challenges of disease prevention and control. Control focuses on management of Aedes, although these efforts have typically had limited effectiveness in preventing outbreaks. New prevention and control efforts are needed to counter the potential consequences of climate change on the geographic range and incidence of dengue, including novel methods of vector control and dengue vaccines.
more
Guidelines for Handling Temperature Sensitive Vaccines and Pharmaceuticals
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab...a evaluado la eficacia).Entre los participantes sin evidencia de infección previa por SARS-CoV-2, hubo 3 casos de COVID-19 entre los 1.305 receptores de vacuna a partir de los 7 días de la segunda dosis y 16 entre los 663 receptores de placebo.
more
(Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та Spikevax® виробництва Moderna);
Anamnese zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
(Comirnaty® 10 μg bzw. ...30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more
– (Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer... und Spikevax® von Moderna)
more